Thyroid transcription factor-1 (TTF-1) has long been recognized as a marker of lung adenocarcinoma, and retrospective studies have hinted that TTF-1-negative tumors might achieve inferior responses to chemotherapy and, possibly, immunotherapy [11,19]. This evidence concerns the gene TTF1 and lung adenocarcinoma.